Fungal and mycobacterial infections after Campath (alemtuzumab) induction for renal transplantation.
To report our experience with fungal and mycobacterial (tuberculosis) infection following induction with Campath (alemtuzumab). We reviewed the database of 477 renal transplant patients induced with alemtuzumab. All those who had a fungal or mycobacterial infection were found, and the details of these complications reviewed. Five patients were found to have fungal (3) or tuberculous (2) infection. The incidence of fungal infection was 0.6% and that of tuberculous infection was 0.4%. Mortality rates for these 2 types of infection were 50% and 100%, respectively. During the same period, there was an overall mortality of 1.7% (n=5). No surviving patient lost graft function. Although fungal and mycobacterial infections caused significant mortality, the overall incidence remains low and comparable to that associated with other induction agents.